LifeSciences BC > Uncategorized > Qu Biologics Opens Crohn’s Disease Clinical Trial to U.S. Participants

Print Friendly

Qu Biologics Opens Crohn’s Disease Clinical Trial to U.S. Participants

February 18, 2014 – Qu Biologics Inc.

Vancouver, British Columbia – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system, announced that its Crohn’s disease clinical trial is now accepting participants from the U.S.

“Significant patient interest from the United States in our Crohn’s disease clinical trial prompted us to open the trial to Americans,” said Dr. Hal Gunn. “Enrollment into our trial is underway. We are pleased with the progress of the clinical trial and excited about the potential of SSI treatment for Crohn’s disease,” Dr. Gunn commented.

Sixty adults with active moderate-to-severe Crohn’s disease are being recruited to evaluate Qu Biologics’ investigational new treatment, QBECO SSI, for Crohn’s disease. A maximum of 30 U.S. patients will be allowed to participate in this Phase 1/2 Crohn’s disease research trial, located in Vancouver, Canada. The main purpose of this study is to test whether this investigational treatment is safe and effective for the treatment of Crohn’s disease.

Prior to this formal clinical trial, ten patients with Crohn’s disease were treated with QBECO SSI in a compassionate use program. All ten patients reported improvement in symptoms while on SSI treatment. Seven of the ten patients reported full resolution of clinical symptoms with a course of SSI treatment of three months or more. Four of these patients have had sustained clinical remission after discontinuing all medications including SSI treatment. The longest case of clinical remission reported is still ongoing after more than three and a half years. These previous ten patients were treated under a compassionate use program, not a controlled blinded clinical trial, and therefore these results do not provide proof of benefit.

Anyone interested in participating in the Crohn’s disease clinical trial can take a pre-screening questionnaire at

About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body’s immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease. The company is currently recruiting participants for a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn’s disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit and

Julie Jang
Director, Communications
Qu Biologics Inc.
604.734.1450 ext.41491

Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics’ forward-looking statements due to the risks and uncertainties inherent in Qu Biologics’ business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.